Table 2 Antituberculosis drug regimens and dosages.

From: Factors associated with adverse drug reactions or death in very elderly hospitalized patients with pulmonary tuberculosis

 

All patients

No event

ADR or death within 60 days

p value

(n = 632)

(n = 364)

(n = 268)

Antituberculosis drug regimens

632

364

268

 

 HREZ

40 (6.3)

30 (8.2)

10 (3.7)

 

 HRLZ

7 (1.1)

4 (1.1)

3 (1.1)

 

 HRE

441 (69.8)

268 (73.6)

173 (64.6)

 

 HRL

126 (19.9)

55 (15.1)

71 (26.5)

 

 HR

18 (2.8)

7 (1.9)

11 (4.1)

 

Dose of rifampicin and isoniazid

 Isoniazid dose/BW, mg/kg/day

5.1 (4.5–5.7)

5.0 (4.5–5.7)

5.1 (4.5–5.7)

0.673

  Isoniazid < 4 mg/kg/day

51 (8.1)a

35 (9.6)a

16 (6.0)a

0.096

 Rifampicin dose/BW, mg/kg/day

7.1 (6.1–8.6)

7.0 (6.0–8.4)

7.5 (6.4–9.0)

0.001

  Rifampicin < 8 mg/kg/day

416 (65.8)b

255 (70.1)b

161 (60.1)b

0.009

  1. HREZ, isoniazid, rifampicin, ethambutol, pyrazinamide; HRLZ, isoniazid, rifampicin, levofloxacin, pyrazinamide; HRE, isoniazid, rifampicin, ethambutol; HRL, isoniazid, rifampicin, levofloxacin; HR, isoniazid, rifampicin; ADR, adverse drug reactions; BW, body weight.
  2. Data are presented as the number (percent) or median (interquartile range).
  3. aMedian (interquartile range) values of INH dosage in all patients, those with no event, and those with ADR or death within 60 days were 3.7 (3.5–3.9), 3.6 (3.4–3.8), and 3.7 (3.6–3.9), respectively.
  4. bMedian (interquartile range) values of RIF dosage in all patients, those with no event, and those with ADR or death within 60 days were 6.4 (5.8–7.1), 6.4 (5.8–7.0), and 6.5 (5.9–7.1), respectively.
Back to article page